Chair: Anthony DAmico, MD, PhD, FASTRO Brigham And Women's Hospital
- Professor, Radiation Oncology, Harvard Medical School
- Chief, Genitourinary Radiation Oncology, Brigham And Women's Hospital
- Chief, Genitourinary Radiation Oncology, Dana-Farber Cancer Institute
- DF/HCC PROGRAM AFFILIATION Prostate Cancer, Member
- Research - My research is focused on two levels. At the basic science
level, I have independent funding to support work in two laboratories.
One lab is investigating the effect that benign prostatic epithelial and
stromal cells have on the growth of juxtaposed malignant prostatic
epithelial cells. This work aims to explain an improved PSA failure
survival that I noted in prostate cancer patients managed with RT or
surgery who also had moderate benign prostatic hypertrophy. The second
lab is dedicated to the synthesis of prostate specific antigen
cleavable pro-drugs whose target is the androgen independent metastatic
prostate cancer cell.
On the clinical research level, I am the principal
investigator of a national phase II prospective trial which will
determine ability of endorectal coil MRI to assess androgen
responsiveness and outcome (cause-specific and overall survival) after
external beam radiation therapy and androgen suppression therapy for
prostate cancer. I am also the principal investigator of a phase III
prospective randomized trial evaluating the impact on survival
(cause-specific and overall) from the addition of androgen suppression
therapy to external beam radiation therapy for localized prostate
cancer. I have developed a staging system for clinically localized
prostate cancer from retrospective data analysis of radiation and
surgically managed patients and with others I am prospectively
attempting to validate it. Other retrospective studies that I am
leading include identification of the optimal patients for interstitial
prostate brachytherapy, external beam plus interstitial prostate
brachytherapy, and androgen suppression plus external beam and
interstitial prostate brachytherapy. These studies will be the basis
for patient selection for prospective trials assessing the relative
efficacy of these treatments on cause-specific and overall survival.
Speakers:
- Alan Pollack, MD, PhD
- Biography - Dr. Pollack is Professor and Chair of the Department of Radiation
Oncology at Miller School of Medicine. He obtained a Ph.D. in
Microbiology and Immunology from the University of Miami and after 5
years of translational research matriculated at the University of Miami
Miller School of Medicine in the Ph.D. to M.D. program. After
graduating, he did an internship in internal medicine at Jackson
Memorial Hospital before doing a residency in radiation oncology at M.D.
Anderson Cancer Center in Houston. While at M.D. Anderson, Dr. Pollack
attained the rank of Professor, was Director of the Residency Training
Program and was a co-leader of the GU group before assuming the Chair in
Radiation Oncology Position at Fox Chase Cancer Center in Philadelphia
in 2001. He held that position for 7 years before returning to Miami in
his current position as Chair and Professor of Radiation Oncology in
2008
- Research Interests - Dr. Pollack’s research interests have centered on
the management of prostate cancer with radiotherapy (RT), with and
without androgen deprivation therapy (ADT). An emphasis has been placed
on dose escalation, fractionation, length of ADT, tissue and imaging
markers of outcome and small molecule/gene/viral vector targeted
therapy. Dr. Pollack’s quantitative imaging research on men with
prostate cancer who are candidates for active surveillance is funded by
the NCI. He co-leads the genitourinary translational research program in
the NRG cooperative group and has published a series of papers on
biomarkers that predict response to RT ± ADT for men treated on
cooperative group trials. Many of these biomarkers are potential
treatment targets and some of these targets have been investigated by
Dr. Pollack Dr. Pollack has been the lead principal investigator on
several clinical trials, including an ongoing Sylvester
investigator-initiated trial of MRI-guided radiotherapy (BLaStM) and a
national RTOG/NRG study (SPPORT, 0534) that has reached the accrual
goal.
- Thomas Wiegel, MD
- Biography - since 2005 Head of Department fo Radiation Oncology, University Hospital Ulm/Germany; 1998 – 2004 Assistant Professor and Vice Director, Department of Radiation Oncology, Charité –Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin/Germany; 1994 – 2005 Fellow, Department of Radiation Oncology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin/Germany; 1991 – 1994 Fellow, Department of Radiation Oncology, University Hospital Hamburg/Germany; 1989 – 1991 Resident, Department of Radiation Oncology, University Hospital Hamburg/Germany
- Research - The
“Prostate Cancer Outcomes” project aims to contribute to improving the
physical and mental health of men being treated for localised prostate
cancer. The intention of this global project is to systematically
measure and (anonymously) compare clinical and patient-reported
endpoints (what are known as Patient Reported Outcomes – PROs) for
localised prostate cancer in clinics from several countries. In this
context all participating clinics use, in a prospective manner, a
standardised data set to measure patient-reported endpoints, which
contains EPIC 26, an internationally established questionnaire for the
measurement of health-related quality of life. Furthermore, other
variables are measured which have the potential to influence these
endpoints (e.g. pre- and post-therapeutic treatment regimens, work in
multidisciplinary teams, etc.) Almost all these variables are already
fully reported by the centres for the audits in conjunction with DKG
certification. Based on these data the different results are to be
analysed and characteristics identified for the best possible care.
Besides the exchange of knowledge between the participating centres, the
project likewise aims to disseminate knowledge beyond this circle.
- Christopher J. Kane, MD Chair, Department of Urology, Professor of Urology, UC San Diego
- Biography - Prior to joining UC San
Diego Health, Dr. Kane held leadership positions at UC San Francisco
and the Naval Medical Center San Diego. He was awarded the Distinguished
Engineering Alumni Medal by UC Davis in 2011. In 2014 he was elected to
membership in the American Association of Genitourinary Surgeons. He is
a retired Navy Captain and a decorated veteran of Desert Storm. Dr.
Kane completed his residency at the Naval Medical Center in Oakland,
California. He received his medical degree from Uniformed Services
University of the Health Sciences in Bethesda, Maryland. Dr. Kane is
board-certified in urology.
- Clinical Practice - Christopher J. Kane, MD, is a board-certified urologic oncologist. He
has a special interest in treating patients with prostate cancer and has
extensive expertise in robotic prostatectomy, open and laparoscopic
kidney cancer surgery, and bladder and testes cancer surgery. Dr.
Kane performs over 200 robotic cancer surgeries per year and is highly
experienced in nerve sparing robotic prostatectomies, robotic radical
cystectomy for bladder cancer, and robotic partial nephrectomy for
kidney cancer.
- Research - He is internationally recognized for patient care and
research in prostate cancer, renal cell carcinoma, robotic and minimally
invasive surgical treatment of urologic diseases and disorders, and
risk stratification and outcomes after treatment.
Dr. Kane has
authored more than 240 peer-reviewed research articles with a focus on
prostate cancer risk factors and outcomes, prostate cancer surgery and
minimally invasive surgery for prostate and kidney cancer. He serves on
the editorial boards of several major urology journals as well as the
National Comprehensive Cancer Network (NCCN) Prostate Cancer Management
Guidelines Committee. He also co-chairs the National Cancer Institute’s
Renal Cell Carcinoma Advisory Task Force.
- Juanita Crook, MD
- Biography -Dr. Juanita Crook | BC Cancer Foundation Dr. Crook is a Professor of Radiation Oncology at the University of
British Columbia and on staff at the Cancer Centre for the Southern
Interior in Kelowna, B.C. She is a recognized expert in the field of
brachytherapy for prostate cancer and penile cancer.
- Research - Her research has
included predictive factors for post implant toxicity, guidelines for
the reporting of critical organ doses following brachytherapy and she
has led the way in the use of MRI-CT fusion for quality assurance of
prostate brachytherapy. She has written 23 book chapters, over 150
journal articles and is a frequent speaker at international meetings, in
English, French and Spanish. She was Scientific Chair of the 2007
American Brachytherapy Society (ABS) meeting, regularly teaches at the
ABS Prostate Brachytherapy School and is past president and chairman of
the Board of the ABS.
|
DESCRIPTION:
The
specific scenarios included 3 case histories of men with newly diagnosed localized,
locally advanced, post-operative pT3,4 and/or margin + disease in the
setting of an undetectable PSA in addition to post-operative or
post-radiation PSA recurrence. An audience interactive format was
used to enhance learning and provide an opportunity to ask additional
questions.
- Initial Case
- Recurrence Case
- Recurrence Case
|
No comments:
Post a Comment